Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
|
EQS-News: Galimedix, Inc.
/ Key word(s): Study
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Kensington, MD, USA and Munich/Martinsried, Germany, May 6, 2025 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the completion of the single ascending dose (SAD) part of the Phase 1 study with orally administered GAL-101, a small molecule specifically designed to target misfolded amyloid beta (Aβ) monomers. In the SAD part of the study, a total of 40 healthy volunteers were randomized 3:1 to receive GAL-101 capsules or placebo capsules. The results showed that GAL-101 was well tolerated with a highly favorable safety profile. GAL-101 also demonstrated an excellent pharmacokinetic profile, strongly supporting the planned oral administration route. “The successful completion of the single ascending dose part of our Phase 1 trial with oral GAL-101 marks an important step forward in our clinical development,” said Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer of Galimedix. “The data we have seen so far support the safety, tolerability and pharmacokinetic profile we anticipated and reinforce the potential of GAL-101 as an oral therapy for CNS, eye and other diseases associated with amyloid beta pathology, including Alzheimer’s disease. We are proceeding according to plan and are now moving confidently into the next parts of the study, which we are on track to complete later this year.” The ongoing Phase 1 trial is designed to enroll up to 120 participants, addressing all relevant aspects required to initiate the planned oral Phase 2 studies in Galimedix´s key indications, namely Alzheimer’s disease, dry AMD and glaucoma. Galimedix also is conducting a Phase 2 clinical trial with GAL-101 eyedrops for dry AMD; the eDREAM study is expected to complete recruitment in less than a year from now. About GAL-101 In a previous Phase 1 study, GAL-101 eyedrops demonstrated an excellent safety and tolerability profile. In pre-clinical testing, the compound has been shown to prevent and eliminate all forms of toxic Aβ species while leaving healthy Aβ forms intact. GAL-101 has also demonstrated the potential for neuroprotection and for symptomatic alleviation in pre-clinical models of Alzheimer’s disease. Additionally, orally available GAL-101 has shown no antibody-specific immunological side effects (e.g., ARIA), very low systemic toxicity, robust storage stability, and easy and inexpensive manufacturing. Strong efficacy has also been demonstrated in relevant ophthalmic pre-clinical models, protecting neuronal retinal cells from toxic damage. A Phase 2 study (NCT06659549) in dry AMD with GAL-101 eyedrops is ongoing. About Galimedix Therapeutics, Inc.
Contact
06.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2130800 06.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.